Analysis of Bevacizumab Activity Following Treatment of Patients with Ovarian Cancer or Glioblastoma

Highly sensitive reporter-gene assays have been developed that allow the precise quantification of both direct vascular endothelial growth factor-A neutralizing activity bevacizumab and ability to activate antibody dependent cellular cytotoxicity. The use these analyzes samples from patients with ovarian cancer following four cycle treatment revealed a close correlation between cytotoxicity activity, reasonably good activities circulating drug levels determined using an enzyme-linked immunosorbent assay. Analysis longitudinal small cohort glioblastoma treated lower parameters. We report herein reanalysis grouped two studies nonparametric Spearman rank coefficient surprisingly facets despite different indications regimens, revealing new insights into action in neoplastic disease.